Immunostimulatory oligodeoxynucleotides induce apoptosis of B cell chronic lymphocytic leukemia cells.
about
Immune Reactivation by Cell-Free Fetal DNA in Healthy Pregnancies Re-Purposed to Target Tumors: Novel Checkpoint Inhibition in Cancer TherapeuticsToll-like receptors on B-CLL cells: expression and functional consequences of their stimulation.Toll-like receptor 9 signaling by CpG-B oligodeoxynucleotides induces an apoptotic pathway in human chronic lymphocytic leukemia B cells.B-CLL cells acquire APC- and CTL-like phenotypic characteristics after stimulation with CpG ODN and IL-21Vaccine adjuvant materials for cancer immunotherapy and control of infectious diseaseTLR-9 and IL-15 Synergy Promotes the In Vitro Clonal Expansion of Chronic Lymphocytic Leukemia B Cells.CpG oligodeoxynucleotide CpG-685 upregulates functional interleukin-21 receptor on chronic lymphocytic leukemia B cells through an NF-κB mediated pathwayProgress in drug development of immunostimulatory CpG oligodeoxynucleotide ligands for TLR9.Phase I clinical trial of CpG oligonucleotide 7909 (PF-03512676) in patients with previously treated chronic lymphocytic leukemiaIL-21 mediates apoptosis through up-regulation of the BH3 family member BIM and enhances both direct and antibody-dependent cellular cytotoxicity in primary chronic lymphocytic leukemia cells in vitroToll-like receptor agonists in the treatment of chronic lymphocytic leukemia.Development of TLR9 agonists for cancer therapyPatients with chronic lymphocytic leukaemia (CLL) differ in the pattern of CTLA-4 expression on CLL cells: the possible implications for immunotherapy with CTLA-4 blocking antibodyToll-like receptor agonists induce apoptosis in mouse B-cell lymphoma cells by altering NF-κB activation.Toll-like receptor 9 (TLR9) agonists in the treatment of cancer.Toll-like receptors and immune regulation: implications for cancer therapy.Toll-like receptors: lessons to learn from normal and malignant human B cellsThe role of toll-like receptors in chronic B-cell malignancies.Stimulating natural killer cells to protect against cancer: recent developments.Stereotyped B-cell receptors in chronic lymphocytic leukemia.Interleukin 21 - its potential role in the therapy of B-cell lymphomas.Toll-like receptors targeting technology for the treatment of lymphoma.Autophagy links pattern recognition receptors to tumor cell apoptosis.Acute lymphoblastic leukemia cells treated with CpG oligodeoxynucleotides, IL-4 and CD40 ligand facilitate enhanced anti-leukemic CTL responses.Toll-like receptors mediate proliferation and survival of multiple myeloma cells.Differential immune effects mediated by Toll-like receptors stimulation in precursor B-cell acute lymphoblastic leukaemia.B-chronic lymphocytic leukemia cells and other B cells can produce granzyme B and gain cytotoxic potential after interleukin-21-based activation.CD5+ B cells from individuals with systemic lupus erythematosus express granzyme B.Combined treatment of CpG-oligodeoxynucleotide with Nutlin-3 induces strong immune stimulation coupled to cytotoxicity in B-chronic lymphocytic leukemic (B-CLL) cells.Lack of Associations between TLR9 and MYD88 Gene Polymorphisms and Risk of Chronic Lymphocytic LeukemiaMyeloid cell leukaemia 1 has a vital role in retinoic acid-mediated protection of Toll-like receptor 9-stimulated B cells from spontaneous and DNA damage-induced apoptosis.The Akt signaling pathway determines the different proliferative capacity of chronic lymphocytic leukemia B-cells from patients with progressive and stable disease.The miR-17∼92 family regulates the response to Toll-like receptor 9 triggering of CLL cells with unmutated IGHV genes.The novel antisense Bcl-2 inhibitor SPC2996 causes rapid leukemic cell clearance and immune activation in chronic lymphocytic leukemia.Inflammation and multiple myeloma: the Toll connection
P2860
Q26784480-7212AF67-9DA8-4DDF-83C6-9A8ECA5F9709Q33494116-24FD1C73-23AF-4D0A-B5E6-A27CE49E084AQ33931707-50F8C52F-BED9-40B2-9474-8DD3159B6BAAQ34048170-79FF3A12-9D6D-472D-AE8D-BF5CDFA9BB99Q35035612-26B3B6EA-E95F-4C8E-BCA6-BE38609BBC63Q35861964-E8BDC770-5F06-4EE9-A93C-97835FB628ECQ36140670-92E02C31-1761-4F98-AB18-ADAC5DC20241Q36150499-949BAA81-6896-4132-8755-88617DACB8EAQ36222910-04491C87-1726-43F7-B6D7-F9FECFF3286BQ36591370-5E2BC367-2366-421A-B33F-57EE436FC2D8Q36635059-DA87246F-3FF9-4110-A394-0ED3A9AC70D3Q36809776-CC3346B4-74BE-4C0A-90E9-AA86D01110A5Q36834544-2D53A6BC-9645-4AD3-B12B-17E7C6DDCA05Q36979947-33360256-C074-4C5D-8BB0-50EDCA8FA164Q37050998-AE9CBD05-5EDE-470B-A80F-3F7084539C38Q37051007-68380A5C-569F-48DB-9B59-CA23B82509A8Q37203723-4E913743-F5A3-4730-AF60-A5FD32088909Q37578343-AE22D9EF-9435-4F45-9670-31118BC5DE3CQ37877269-3FC9D641-08B0-4726-9F9B-F111F800D8CBQ38176427-1C629CD1-CBE4-4F09-8F0A-E38A2ACB2A02Q38894228-2D9D04B0-6A71-47A4-B5C4-1EBB59F6B223Q38948266-7582F653-0CA4-46D2-A95A-1893E131FB1EQ39502795-6CCAAE80-C936-4750-B865-90FAB6316357Q39551385-6D9FBBC3-1731-4127-84E9-10820CCD1AAAQ40291993-5727B95C-E977-42E9-8BAF-5716BA9F6D13Q40330092-E5311E7D-267F-4061-8446-2561CD634B40Q42742024-4169A456-4D0B-469C-A330-4AB82A8B0971Q45176452-9484FEBB-3020-4501-8007-ACCBE0CCA2C7Q46903202-8A70E3CF-BB0E-40C9-9820-591B3F3A05D9Q47212613-2FB1571B-5987-4148-B6E8-6009AC2F4CD0Q51712946-4E9D9476-85FC-4A6E-8EDD-46D4FE448AB8Q53595110-891E0431-53C5-42E6-A5DE-6C1A596C9138Q54323506-1570F087-ED05-4C1E-B246-7A4421627C3EQ54385532-B2805F73-1FDD-44D4-B967-EC5E71075DDDQ56942850-46B0CF07-146E-495C-93B6-23CD94152613
P2860
Immunostimulatory oligodeoxynucleotides induce apoptosis of B cell chronic lymphocytic leukemia cells.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年学术文章
@wuu
2004年学术文章
@zh-cn
2004年学术文章
@zh-hans
2004年学术文章
@zh-my
2004年学术文章
@zh-sg
2004年學術文章
@yue
2004年學術文章
@zh
2004年學術文章
@zh-hant
name
Immunostimulatory oligodeoxynu ...... ic lymphocytic leukemia cells.
@en
type
label
Immunostimulatory oligodeoxynu ...... ic lymphocytic leukemia cells.
@en
prefLabel
Immunostimulatory oligodeoxynu ...... ic lymphocytic leukemia cells.
@en
P2093
P2860
P921
P356
P1476
Immunostimulatory oligodeoxynu ...... nic lymphocytic leukemia cells
@en
P2093
Bernd Jahrsdörfer
Christiana M Taylor
James E Wooldridge
Sue E Blackwell
Thomas S Griffith
P2860
P304
P356
10.1189/JLB.0604373
P577
2004-12-06T00:00:00Z